Improving delivery of safe and effective treatments
Rare cancers account for more than 20 percent of new cancer diagnoses, underscoring the fact that developing treatments for these conditions demands expertise in both oncology and rare disease. Growing cooperation among big pharma, biotech companies, and academia and a more favorable regulatory environment are accelerating development of novel therapies.
In our white paper, you’ll learn:
- How new regulatory initiatives can expedite review and approval of investigative drugs
- Pros and cons of adaptive design
- The expanding importance of study committees such as institutional review boards and steering committees